Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Trinity Medical Wny PC

Neither a doctor nor a teaching hospital

Research payments

$211,156

129 payments

Through program year 2025, Trinity Medical Wny PC is reported as receiving $211,156 in research payments, across 129 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $3,000 1
2024 Research $38,803 3
2022 Research $4,500 5
2021 Research $85,623 50
2020 Research $40,567 43
2019 Research $38,663 27

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $69,031 7 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $54,455 19 payments
  3. AstraZeneca UK Limited $28,061 4 payments
  4. Boston Scientific Corporation $20,619 21 payments
  5. Biotronik Inc. $10,118 58 payments
  6. Vifor (International) Ltd. $10,000 4 payments
  7. Merck Sharp & Dohme Corporation $8,711 5 payments
  8. Abbott Laboratories $7,761 10 payments
  9. Sanofi US Services Inc. $2,400 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction Persistent Inflammation and Elevated N terminal Prohormone Brain Natriuretic Peptide $73,762 8 payments
  2. Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction $41,805 16 payments
  3. Smart Registry $15,220 16 payments
  4. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $15,100 2 payments
  5. Multicenter randomized placebo-controlled double-blind parallel group dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke $12,650 3 payments
  6. Bio-Libra $10,118 58 payments
  7. Diamond Pat-Cr-302 $10,000 4 payments
  8. A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA $8,711 5 payments
  9. Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $8,231 1 payment
  10. MultiPoint Pacing Post Market Study $5,386 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record